Stock Market news at lse.co.uk - RSS News Feeds

Oxford Biomedica Share News (OXB)



Share News for Oxford Biomedica (OXB)


Share Price: 1.74Bid: 1.68Ask: 1.72Change: 0.04 (+2.35%)Riser - Oxford Biomed.
Spread: 0.04Spread as %: 2.38%Open: 1.70High: 1.70Low: 1.70Yesterday’s Close: 1.70




BRIEF-Oxford BioMedica gets new finance head

Fri, 10th Feb 2012 07:21

LONDON, Feb 10 (Reuters) - Oxford BioMedica PLC:

* Appointment of new chief financial off
icer

* Tim Watts has been appointed to the board as chief financial officer with

immediate effect

((London Equities Newsroom; +44 20 7542 7717))



(For more news, please click here)

COPYRIGHT
Copyright Thomson Reuters 2012. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.


Related Shares: Oxford Biomedica (OXB) 





STOCKS NEWS EUROPE-UK small caps drop 0.5 percent

UK small caps fall 0.5 percent, underperforming both the midcaps, off 0.3 percent, and the FTSE AIM All Share index, 0.2 percent firmer.Gene-based bio
[3 Jun '13]

Oxford BioMedica pauses some trials after finding potential impurities

June 3 (Reuters) - Gene-based biopharmaceutical company Oxford BioMedica said it put some of its trials on hold, after the company detected very low c
[3 Jun '13]

STOCKS NEWS EUROPE-Oxford BioMedica up on Novartis deal

Shares in Oxford BioMedica rise 15 percent after the gene-based biopharmaceutical specialist signs a deal to make clinical grade material for Novartis
[1 May '13]

STOCKS NEWS EUROPE-UK small caps edge down 0.1 pct early on

The FTSE Small Cap index sheds 0.1 percent in early deals, underperforming its larger peers with the FTSE 100 up 0.4 percent and the FTSE 250 rising 0
[1 May '13]

BRIEF-Oxford Biomedica says ImaginAb exercises option for licence

LONDON, Nov 29 (Reuters) - Oxford BioMedica PLC: * Imaginab acquires exclusive worldwide licence for 5t4-based imaging diagnostic
[29 Nov '12]

UPDATE 1-Oxford Bio abandons prostate cancer vaccine study

LONDON, Oct 10 (Reuters) - Britain's Oxford BioMedica said on Wednesday it was closing a mid-stage clinical trial of its cancer vaccine TroVax
[10 Oct '12]

BRIEF-Oxford Bio to close prostate cancer study in U.S.

LONDON, Oct 10 (Reuters) - Oxford BioMedica PLC: * To close phase II study in US to assess Trovax in patients with prostate cancer
[10 Oct '12]

BRIEF-Oxford Biomedica to place 11 mln stg

LONDON, June 29 (Reuters) - Oxford BioMedica PLC: * Proposed firm placing of £11 million and open offer of up to £5 million ((London
[29 Jun '12]



Sign up for Live Prices





Datafeed and UK data supplied by NETbuilder and Interactive Data. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.